FR2634377B1 - Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif - Google Patents

Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif

Info

Publication number
FR2634377B1
FR2634377B1 FR8809046A FR8809046A FR2634377B1 FR 2634377 B1 FR2634377 B1 FR 2634377B1 FR 8809046 A FR8809046 A FR 8809046A FR 8809046 A FR8809046 A FR 8809046A FR 2634377 B1 FR2634377 B1 FR 2634377B1
Authority
FR
France
Prior art keywords
extended release
release pharmaceutical
pharmaceutical form
form based
active resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR8809046A
Other languages
English (en)
Other versions
FR2634377A1 (fr
Inventor
Rosa Martani
Elisabeth Le Huede
Jeanne Dumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortial SA
Original Assignee
Cortial SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortial SA filed Critical Cortial SA
Priority to FR8809046A priority Critical patent/FR2634377B1/fr
Priority to EP89450008A priority patent/EP0349453A1/fr
Priority to PT91003A priority patent/PT91003A/pt
Priority to ES8902279A priority patent/ES2016033A6/es
Priority to MA21835A priority patent/MA21586A1/fr
Priority to ZA896286A priority patent/ZA896286B/xx
Publication of FR2634377A1 publication Critical patent/FR2634377A1/fr
Application granted granted Critical
Publication of FR2634377B1 publication Critical patent/FR2634377B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
FR8809046A 1988-06-30 1988-06-30 Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif Expired - Fee Related FR2634377B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR8809046A FR2634377B1 (fr) 1988-06-30 1988-06-30 Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
EP89450008A EP0349453A1 (fr) 1988-06-30 1989-04-21 Nouvelle forme pharmaceutique à libération prolongée à base d'un complexe résine-principe actif
PT91003A PT91003A (pt) 1988-06-30 1989-06-28 Processo para a preparacao de uma nova forma farmaceutica de libertacao prolongada a base de um complexo de resina-principio activo
ES8902279A ES2016033A6 (es) 1988-06-30 1989-06-28 Procedimiento de obtencion de una nueva forma farmaceutica de libeeracion prolongada basada en un complejo resina-principio activo.
MA21835A MA21586A1 (fr) 1988-06-30 1989-06-29 Procede de preparition d'une nouvelle forme pharmaceutique a liberation prolongee comprenant un complexe resine principe actif.
ZA896286A ZA896286B (en) 1988-06-30 1989-08-17 New extended release pharmaceutical form based on a resin/active principle complex

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8809046A FR2634377B1 (fr) 1988-06-30 1988-06-30 Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif

Publications (2)

Publication Number Publication Date
FR2634377A1 FR2634377A1 (fr) 1990-01-26
FR2634377B1 true FR2634377B1 (fr) 1991-09-27

Family

ID=9368055

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8809046A Expired - Fee Related FR2634377B1 (fr) 1988-06-30 1988-06-30 Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif

Country Status (5)

Country Link
EP (1) EP0349453A1 (fr)
ES (1) ES2016033A6 (fr)
FR (1) FR2634377B1 (fr)
MA (1) MA21586A1 (fr)
PT (1) PT91003A (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7910133B2 (en) 2002-04-09 2011-03-22 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
HUT74642A (en) * 1990-12-21 1997-01-28 Richardson Vicks Inc Polyamine drug-resin complex
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
CA2178620A1 (fr) * 1993-12-08 1995-06-15 Lisa B. Jungherr Systeme de liberation de medicament a microbilles
ES2097087B1 (es) * 1994-08-01 1997-12-16 Univ Sevilla Sistema de liberacion controlada de morfina y otros farmacos solubles en agua por complejacion con sustancias polimericas.
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
PL1732523T3 (pl) 2004-03-30 2010-08-31 Vifor Pharma Tech Ltd Polimery wiążące potas i ich zastosowania
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
PT3219312T (pt) * 2004-03-30 2019-03-01 Relypsa Inc Polímeros de ligação a ião e seus usos
US8586097B2 (en) 2005-09-30 2013-11-19 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
US8617609B2 (en) 2005-09-30 2013-12-31 Relypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
BR112015007749A2 (pt) 2012-10-08 2017-07-04 Relypsa Inc métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246037B2 (de) * 1972-09-20 1975-02-27 Taeschner & Co, 8831 Kipfenberg Peroral anwendbares Arzneimittel mit verzögerter Resorbierbarkeit in Suspensionsform

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7910133B2 (en) 2002-04-09 2011-03-22 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin

Also Published As

Publication number Publication date
FR2634377A1 (fr) 1990-01-26
EP0349453A1 (fr) 1990-01-03
MA21586A1 (fr) 1990-04-01
ES2016033A6 (es) 1990-10-01
PT91003A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
FR2634377B1 (fr) Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
FR2624732B1 (fr) Formulation pharmaceutique a liberation prolongee
IT8603467A0 (it) Farmaci ad attivita'antiflogistica nuove formulazioni galeniche a cessione programmata contenenti
FR2598148B1 (fr) Formulations a base d'amidon.
FR2664163B1 (fr) Forme posologique pharmaceutique solide orale a liberation programmee.
FR2518409B1 (fr) Preparations therapeutiques a liberation prolongee a base d'hydroxypropylmethylcellulose
IT8948369A0 (it) Composizioni farmaceutiche a base di ciclosporine
FR2642650B1 (fr) Nouvelles compositions pharmaceutiques a base de cyclosporines
FR2643263B1 (fr) Composition pharmaceutique a base de ranitidine
FR2600253B1 (fr) Nouvelles compositions pharmaceutiques a base de ketotifene
FR2614790B1 (fr) Nouvelle composition ophtalmologique a base d'acide eicosapeutaenoique
FR2604902B1 (fr) Compositions pharmaceutiques a liberation prolongee
FR2634125B1 (fr) Composition pharmaceutique a base de superoxyde dismutase
FR2661830B1 (fr) Nouvelle compositions pharmaceutiques a base de flavonoside.
IT1229231B (it) Aminoimidazopiridine farmacologicamente attive
GB2246072B (en) Solid pharmaceutical compositions containing a light sensitive active ingred ient and stabilised by a dye
FI914436A0 (fi) Foerfarande foer framstaellning av baktericida matriser.
FR2589732B1 (fr) Nouvelle formulation a liberation prolongee a base de pindolol
FR2521997B1 (fr) Nouvelle association medicamenteuse a base de morniflumate
MC2109A1 (fr) Dérivés d'acides aminés
FR2605885B1 (fr) Association medicamenteuse a base d'un inhibiteur calcique
FR2594334B1 (fr) Composition pharmaceutique injectable a base d'amoxicilline
OA09301A (fr) "Nouvelle forme galénique orale améliorant la biodisponibilité".
IT1222698B (it) Composti a base di 7-ossabiciclo (2.2.1) eptano aventi attivita' farmaceutica
PT100896A (pt) Composicao farmaceutica para a neutralizacao da interleuquina-1(il-1) utilizando dsrna's

Legal Events

Date Code Title Description
ST Notification of lapse